Table 1. Patient characteristics.
| Total (132) | CGH (59) | |
|---|---|---|
| Median age (range), years | 55 (20–86) | 57 (20–86) |
| Sex | ||
| Male: Female | 67: 65 | 28: 31 |
| Tumor sample | ||
| Primary tumor | 108 (82%) | 46 (78%) |
| Relapsed | 24 (18%) | 13 (22%) |
| Stage | ||
| I | 35/114 (31%) | 15/49 (31%) |
| II A | 26/114 (23%) | 9/49 (18%) |
| II B | 17/114 (15%) | 5/49 (10%) |
| III A | 16/114 (14%) | 7/49 (14%) |
| III B | 3/114 (3%) | 2/49 (4%) |
| IV A | 5/114 (4%) | 3/49 (6%) |
| IV B | 12/114 (11%) | 8/49 (16%) |
| Na* | 18 | 10 |
| Completeness of resection | ||
| R0 | 79/112 (71%) | 33/47 (70%) |
| R1 | 23/112 (21%) | 7/47 (14%) |
| R2 | 10/112 (9%) | 7/47 (14%) |
| Na* | 20 | 12 |
| WHO histotype | ||
| A | 15/132 (11%) | 12/59 (20%) |
| AB | 28/132 (21%) | 14/59 (24%) |
| B1 | 24/132 (18%) | 0 |
| B1/B2 | 6/132 (5%) | 0 |
| B2 | 8/132 (6%) | 1/59 (2%) |
| B2,B3 | 11/132 (8%) | 5/59 (8%) |
| B3 | 24/132 (18%) | 20/59 (34%) |
| C | 14/132 (11%) | 7/59 (12%) |
| Other# | 2/132 (2%) | 0 |
| Paraneoplastic syndromes | ||
| MG | 32/125 (26%) | 17/58 (29%) |
| Other+ | 2/125 (2%) | 1/58 (2%) |
| 10-Year DRS | 87% | 83% |
| 10-Year TTP | 69% | 65% |
Abbreviations: CGH, comparative genomic hybridization; DRS, disease-related survival; MG, myasthenia gravis; Na*, patients for whom data were not available at diagnosis; other#, one micronodular and one cystic thymoma; other+, one autoimmune glomerulonephritis (in the CGH analysis) and one autoimmune encephalopathy; TTP, Time to progression; WHO, World Health Organization